Anti-BCMA CAR T-cell Therapy: Changing the Natural History of Multiple Myeloma

Anti-BCMA CAR T-cell Therapy: Changing the Natural History of Multiple Myeloma

Bibliographic Details
Main Authors:	Borja Puertas, María-Victoria Mateos, Verónica González-Calle
Format:	Article
Language:	English
Published:	Wiley 2022-03-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000691

Similar Items

Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
by: Xiangmin Wang, et al.
Published: (2021-12-01)

sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
by: Katja Seipel, et al.
Published: (2022-03-01)

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
by: Gils Roex, et al.
Published: (2020-12-01)

Single-cell transcriptomic atlas throughout anti-BCMA CAR-T therapy in patients with multiple myeloma
by: Yuan Xia, et al.
Published: (2023-11-01)

CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond
by: Abhinava K. Mishra, et al.
Published: (2023-11-01)

Single VHH-directed BCMA CAR-NK cells for multiple myeloma
by: Quan Ren, et al.
Published: (2023-11-01)

Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
by: Benedetta Dalla Palma, et al.
Published: (2020-09-01)

Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma
by: Surbhi Sidana, et al.
Published: (2023-10-01)

P887: IN-HOUSE ANTI BCMA CAR-T THERAPY FOR THE TREATMENT OF RELAPSED REFRACTORY MULTIPLE MYELOMA: PHASE 1 RESULTS.
by: N. Asherie, et al.
Published: (2022-06-01)

Case report: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy
by: Jingjing Deng, et al.
Published: (2022-09-01)

Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease
by: Haobin Deng, et al.
Published: (2021-08-01)

Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy
by: Di Wang, et al.
Published: (2021-10-01)

BCMA in Multiple Myeloma—A Promising Key to Therapy
by: Martina Kleber, et al.
Published: (2021-09-01)

Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma
by: Rebecca C. Larson, et al.
Published: (2023-11-01)

Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
by: Endeshaw Chekol Abebe, et al.
Published: (2022-09-01)

Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
by: Fumou Sun, et al.
Published: (2024-01-01)

Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
by: Yan Zhang, et al.
Published: (2022-09-01)

BCMA-targeted immunotherapy for multiple myeloma
by: Bo Yu, et al.
Published: (2020-09-01)

A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia
by: Chunrui Li, et al.
Published: (2021-03-01)

271 Development and characterisation of humanised scFv CAR-T therapies targeting BCMA against multiple myeloma
by: Susana Inogés, et al.
Published: (2023-11-01)

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
by: Mehmet Kemal Samur, et al.
Published: (2021-02-01)

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
by: Heng Mei, et al.
Published: (2021-10-01)

NK92 Expressing Anti-BCMA CAR and Secreted TRAIL for the Treatment of Multiple Myeloma: Preliminary In Vitro Assessment
by: Benjamin Motais, et al.
Published: (2023-11-01)

Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma
by: Jinhuan Xu, et al.
Published: (2018-10-01)

Early Dynamics and Depth of Response in Multiple Myeloma Patients Treated With BCMA CAR-T Cells
by: Sandy W. Wong, et al.
Published: (2021-12-01)

Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance
by: Danilo De Novellis, et al.
Published: (2022-12-01)

CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth
by: Robert Berahovich, et al.
Published: (2018-09-01)

Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-β
by: Leah M. Alabanza, et al.
Published: (2022-02-01)

The Gaining Momentum of BCMA-Directed Therapies for Relapsed/Refractory Multiple Myeloma
by: Adrian Schmidt
Published: (2023-10-01)

Targeting BCMA in Multiple Myeloma: Advances in Antibody-Drug Conjugate Therapy
by: Lijie Xing, et al.
Published: (2023-04-01)

P944: A PHASE I STUDY OF C-CAR088, A NOVEL HUMANIZED ANTI-BCMA CAR T CELL THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: X. Qu, et al.
Published: (2022-06-01)

Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma
by: Hujun Li, et al.
Published: (2022-10-01)

Role of Anti-B-Cell Maturation Antigen (BCMA) in the Management of Multiple Myeloma
by: Ikhwan Rinaldi, et al.
Published: (2022-07-01)

Anti‐BCMA Immuno‐NanoPET Radiotracers for Improved Detection of Multiple Myeloma
by: Thomas, Eloise, et al.
Published: (2022)

Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma
by: Vita Golubovskaya, et al.
Published: (2021-10-01)

P889: POINT-OF-CARE ANTI-BCMA CAR T-CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH-RISK RELAPSE/REFRACTORY MULTIPLE MYELOMA
by: Hila Magen, et al.
Published: (2023-08-01)

Clinical Outcomes of BCMA CAR-T Cells in a Multiple Myeloma Patient With Central Nervous System Invasion
by: Ting Wang, et al.
Published: (2022-05-01)

Clinical efficacy and safety of combined anti-BCMA and anti-CD19 CAR-T cell therapy for relapsed/refractory multiple myeloma: a systematic review and meta-analysis
by: Han Xu, et al.
Published: (2024-04-01)

BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma
by: Shih-Feng Cho, et al.
Published: (2020-06-01)

BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting
by: James F. Wu, et al.
Published: (2023-07-01)